Shingrix (Herpes Zoster vaccine Recombinant, adjuvanted)

Product menu

Cancer patient looking far, wearing headscarf.

In immunocompromised patients, the rash associated with shingles may more be severe and long lasting than in immunocompetent patients.1

SHINGRIX is available for eligible immunocompromised patients as part of the Shingles National Immunisation Programme

SHINGLES IN IMMUNOCOMPROMISED (IC) PATIENTS

Following primary Varicella-zoster virus (VZV) infection, VZV lies dormant in the sensory dorsal root ganglia. Reactivation of the latent virus leads to the clinical manifestations of shingles and is associated with immune senescence or suppression of the immune system.2

  • Immunocompromised (IC) patients are at increased risk of shingles and its complications compared to the general population.3
  • In IC patients, rash may be severe and long lasting.1
  • In IC individuals, the rash may affect multiple dermatomes.1
  • Disseminated disease is more likely to occur in those who are severely immunocompromised, with a case fatality rate reported to be between 5-15%.1
  • IC patients are more likely to develop recurrent HZ.3
Patient's Shingles Rash

From Dworkin RH et al., Clinical Infectious Diseases, 2007

Learn more about the impact of shingles by viewing our Shingles Awareness Week webinar

WATCH THE VIDEO

Immunocompromised (IC) patients are at increased risk of shingles and its complications compared to the general population.3

Incidence rate of HZ in various Immunocompromised (IC) populations in England 2000-2012 (data from a retrospective cohort study using CPRD) in Adults ≥18 years of age3

Graph to show the incidence of HZ is higher in immunocompromised patients

This graph has been independently created by GSK from the original data (Yanni EA, Ferreira G, Guennec M, et al; BMJ Open 2018)
n = Number of individuals
Incidence rates of HZ in IC populations in England [data from a retrospective cohort study using the Clinical Practice Research Datalink (CPRD) in adults ≥18 years of age (2000-2012)].3

Learn more about SHINGRIX

Red icon, two syringes pointing in opposite directions

Ready to vaccinate?

Explore our range of support tools as you implement the Shingles National Immunisation Programme

IMPLEMENTING THE NATIONAL PROGRAMME

Red patients icon, showing 3 patient figures

What is the impact of shingles?

There is a 1 in 4 lifetime risk of developing shingles in the general population.2 Shingles is a painful disease that can have serious and long-lasting complications1

IMPACT OF SHINGLES

Red circular icon

Learn more about the efficacy and safety profile of SHINGRIX in IC patients

SHINGRIX has been investigated in a range of immunocompromised (IC) patient populations, including solid tumours, haematologic malignancies, renal transplants and autologous haematopoietic stem cell transplants (auHSCT).4-8

IC EFFICACY AND SAFETY DATA

References

  1. UK NICE Clinical Knowledge Summaries (Shingles) August 2021
  2. DH Green Book ch 28a – Shingles. July 2023
  3. Yanni EA, Ferreira G, Guennec M, et al; BMJ Open 2018;8:e020528
  4. Bastidas A, de la Serna J, El Idrissi M, et al.; for the ZOE-HSCT Study Group Collaborators. Effect of recombinant zoster vaccine on incidence of herpes zoster after autologous stem cell transplantation: a randomized clinical trial [suppl]. JAMA. 2019 July;322(2):123-133.
  5. Dagnew AF, Ilhan O, Lee WS, et al.; on behalf of the Zoster-039 Study Group. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019 September;19(9):988-1000.
  6. Vink P, Torelle JMR, Sanchez Fructuoso A, et al.; for the Z-041 Study Group. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase 3, randomized clinical trial. Clin Infect Dis. 2020 January;70(2):181-190.
  7. Vink P, Mignorance ID, Alonso CM, et al.; on behalf of the Zoster-028 Study Group. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: a randomized trial. Cancer. 2019 April;125(8):1301-1312.
  8. Berkowitz EM, Moyle G, Stellbrink HJ, et al for the Zoster-015 HZ/su Study Group. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis. 2015 April;211:1279-1287.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441

SHINGRIX is owned by or licensed to the GSK group of companies.
© 2022 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.

November 2023 | PM-GB-SGX-WCNT-230019 (V2.0)